|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM336555903 |
| 003 |
DE-627 |
| 005 |
20250303000339.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.108948
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1121.xml
|
| 035 |
|
|
|a (DE-627)NLM336555903
|
| 035 |
|
|
|a (NLM)35123058
|
| 035 |
|
|
|a (PII)S1521-6616(22)00028-6
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Carlsson, Emil
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Longitudinal analysis of urinary proteins in lupus nephritis - A pilot study
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 06.05.2022
|
| 500 |
|
|
|a Date Revised 08.03.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Approximately 30% of adult-onset systemic lupus erythematosus (SLE) patients develop lupus nephritis (LN). The gold standard for LN detection involves renal biopsies, invasive procedures not suitable for routine disease monitoring. A urinary biomarker panel comprised of lipocalin-like prostaglandin D synthase (LPGDS), transferrin, alpha-1-acid glycoprotein (AGP-1), ceruloplasmin, monocyte chemoattractant protein 1 (MCP-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) has shown promise to predict LN and response to rituximab at baseline. Whether these proteins predict LN during longitudinal sampling, however, remained unknown. Here, we quantified aforementioned urinary proteins at baseline (N = 25), six and twelve months (N = 17 each) after rituximab treatment. Urine MCP-1 (at six and twelve months) and AGP-1 (at twelve months) levels varied between patients with active vs mildly active/inactive LN. Findings support the use of urinary proteins to detect active LN in ongoing disease monitoring in adult-onset SLE patients, but need to be validated in larger cohorts
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a BILAG
|
| 650 |
|
4 |
|a Biomarker
|
| 650 |
|
4 |
|a Inflammation
|
| 650 |
|
4 |
|a Lupus
|
| 650 |
|
4 |
|a Nephritis
|
| 650 |
|
4 |
|a Protein
|
| 650 |
|
4 |
|a Renal
|
| 650 |
|
4 |
|a Systemic lupus erythematosus
|
| 650 |
|
4 |
|a Urine
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a Rituximab
|2 NLM
|
| 650 |
|
7 |
|a 4F4X42SYQ6
|2 NLM
|
| 650 |
|
7 |
|a Ceruloplasmin
|2 NLM
|
| 650 |
|
7 |
|a EC 1.16.3.1
|2 NLM
|
| 700 |
1 |
|
|a Quist, Alexandra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Davies, Jennifer C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Midgley, Angela
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Smith, Eve M D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bruce, Ian N
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Beresford, Michael W
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hedrich, Christian M
|e verfasserin
|4 aut
|
| 700 |
0 |
|
|a BILAG-BR and MRC MASTERPLANS Consortia
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 236(2022) vom: 30. März, Seite 108948
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:236
|g year:2022
|g day:30
|g month:03
|g pages:108948
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.108948
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 236
|j 2022
|b 30
|c 03
|h 108948
|